Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Bifeprunox Titration in Schizophrenia
NCT00139906Phase 2Completed
- Sponsor
- Solvay
- Start
- Aug 2005
- Primary completion
- Oct 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bifeprunox in schizophrenia, schizoaffective disorder, sponsored by Solvay. Started Aug 2005; status: completed.
02
Drugs
bifeprunox
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT00139906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00139906.